top of page

About
- Our Company
- Our Leadership Team
Science
Products
Pipeline
Newsroom
Contact
Investors
More

Use tab to navigate through the menu items.

Newsroom

All Posts
Publication
News
Leadership Story

SMAD3 Hypomethylation as a Biomarker for Early Prediction of Colorectal Cancer

SMAD3 Hypomethylation as a Biomarker for Early Prediction of Colorectal Cancer

SMAD3 Hypomethylation as a Biomarker for Early Prediction of Colorectal Cancer

Oct 7, 2020

Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction

Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction

Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction

May 12, 2020

Hypermethylation of BEND5 contributes to cell proliferation andis a prognostic marker of colorectal cancer

Hypermethylation of BEND5 contributes to cell proliferation andis a prognostic marker of colorectal cancer

Hypermethylation of BEND5 contributes to cell proliferation andis a prognostic marker of colorectal cancer

Nov 1, 2017

DNA Methylation

Investor Relations

Laboratory Developed Tests Services

Exosome Based Therapies

Clinical Trial Drug Distribution

Health Supplements

Privacy Statement

Data Rights Form

21720 23rd Dr. SE, Suite 275,

Bothell, WA 98021, USA

Email: info@ydesgroup.com

Tel: +1 (206) 888-0858

bottom of page